enGene Therapeutics (ENGN) Interest & Investment Income (2023 - 2026)
enGene Therapeutics (ENGN) posted quarterly Interest & Investment Income of $2.7 million for Q2 2026, up 7.03% year-over-year from $2.5 million in Q2 2025, and down 2.81% quarter-over-quarter from $2.7 million in Q1 2026.
enGene Therapeutics (ENGN) Interest & Investment Income (2023 - 2026) Analysis & Trends
enGene Therapeutics (ENGN) has reported Interest & Investment Income for 4 consecutive years, with $2.7 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Interest & Investment Income rose 7.03% year-over-year to $2.7 million; the TTM figure through Apr 2026 stood at $9.6 million (down 17.3% YoY), while the FY2025 annual figure was $9.4 million, down 9.48% from the prior year.
- Interest & Investment Income retreated to $2.7 million in Q2 2026 per ENGN's latest filing, from $2.7 million in the prior quarter.
- Across five years, Interest & Investment Income topped out at $3.4 million in Q3 2024 and bottomed at $149000.0 in Q2 2023.
- Historically, Interest & Investment Income has averaged $1.9 million across 4 years, with a median of $2.4 million in 2025.
- Annual changes were most pronounced in 2024 — Interest & Investment Income soared 1902.68% — and 2025, when it tumbled 34.69%.
- enGene Therapeutics' Interest & Investment Income stood at $407000.0 in 2023, then jumped by 643.0% to $3.0 million in 2024, then sank by 34.69% to $2.0 million in 2025, then jumped by 34.84% to $2.7 million in 2026.
- Business Quant data shows ENGN's Interest & Investment Income at $2.7 million in Q2 2026, $2.7 million in Q1 2026, and $2.0 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 67.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 27.90 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 28.14 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 115.94 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 10.98 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 5.13 Mn |
| 10 | enGene Therapeutics | 124.11 Mn | 124.11 Mn | - | 2.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | 2.66 Mn |
| Jan 31, 2026 | 2.74 Mn |
| Oct 31, 2025 | 1.98 Mn |
| Jul 31, 2025 | 2.23 Mn |
| Apr 30, 2025 | 2.49 Mn |
| Jan 31, 2025 | 2.73 Mn |
| Oct 31, 2024 | 3.02 Mn |
| Jul 31, 2024 | 3.38 Mn |
| Apr 30, 2024 | 2.98 Mn |
| Jan 31, 2024 | 1.03 Mn |
| Oct 31, 2023 | 407,000.00 |
| Jul 31, 2023 | 394,000.00 |
| Apr 30, 2023 | 149,000.00 |
| Jan 31, 2023 | 167,000.00 |